Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.38 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 2/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22867074 | 0.83 | NLRP3 (0.39) | PTGDR2NLRP3RPS6KA3 | |
| SCHEMBL22802379 | 0.83 | NLRP3 (0.53) | PTGDR2NLRP3 | |
| SCHEMBL22802359 | 0.82 | NLRP3 (0.55) | PTGDR2NLRP3RPS6KA3 | |
| SCHEMBL22867122 | 0.79 | AGBL2 (0.45) | PTGDR2NLRP3AGBL2RXRA | |
| Trifluoroacetic Acid SCHEMBL30163220 | 0.78 | NLRP3 (0.49) | PTGDR2NLRP3 | |
| SCHEMBL19475203 | 0.76 | NLRP3 (0.41) | NLRP3AGBL2RXRA | |
| SCHEMBL21962584 | 0.76 | NLRP3 (0.42) | PTGDR2NLRP3 | |
| SCHEMBL20744313 | 0.76 | RPS6KA3 (0.40) | GPBAR1RPS6KA3CCNCCDK8PDE2A | |
| SCHEMBL30684117 | 0.76 | RPS6KA3 (0.40) | GPBAR1RPS6KA3CCNCCDK8PDE2A | |
| SCHEMBL23012266 | 0.75 | NLRP3 (0.44) | PTGDR2NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002274-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | PTGDR2 2091/4885NLRP3 1/4885GPBAR1 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.